Portal de Periódicos da CAPES

Antitumor Actions of Interferons

1987; Wiley; Volume: 26; Issue: 9 Linguagem: Inglês

10.1111/j.1365-4362.1987.tb02304.x

1365-4632

Stephen K. Tyring,

Vascular Tumors and Angiosarcomas

International Journal of DermatologyVolume 26, Issue 9 p. 549-556 Antitumor Actions of Interferons Direct, Indirect, and Synergy with Other Treatment Modalities Stephen K. Tyring M.D., Ph.D., Corresponding Author Stephen K. Tyring M.D., Ph.D. From the Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, and the Department of Microbiology, University of Texas Medical Branch, Galvesion, TexasAddress for correspondence: Stephen K. Tyring, M.D., Ph.D., Department of Dermatology, U.A.B./University Station, Birmingham, Al. 35294.Search for more papers by this author Stephen K. Tyring M.D., Ph.D., Corresponding Author Stephen K. Tyring M.D., Ph.D. From the Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, and the Department of Microbiology, University of Texas Medical Branch, Galvesion, TexasAddress for correspondence: Stephen K. Tyring, M.D., Ph.D., Department of Dermatology, U.A.B./University Station, Birmingham, Al. 35294.Search for more papers by this author First published: November 1987 https://doi.org/10.1111/j.1365-4362.1987.tb02304.xCitations: 16AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Ito M, Buffet R. Cytocidal effects of purified human fibroblast interferon on tumor cells in vitro. JNCI. 1981; 66: 819– 825. 2 Le J, Yip YD, Vilcek J. Cytolytic activity of interferon gamma and its synergism with 5-fluornuracil. Int J Cancer. 1984; 34: 495– 500. 3 Tyring S, Klimpel CR, Fleischmann WR Jr, et al. Diret cytolysis by partially-purified preparations of immune interferon. Int J Cancer. 1982; 30: 59– 64. 4 Trichieri C, Santoli D, Doc RR, et al. Antiviral activity induced by culturing lymphocytes with tumor derived or virus-transformed cells: identification of the antiviral activity as interferon and characterization of the human effector lymphocyte subpopulation. J Exp Med. 1978; 147: 1299– 1313. 5 Chapes SK, Tompkins WF. Cytotoxic macrophages induced in hamsters by vaccinia virus: selective cytotoxicity for virus-infected targets by macrophages collected late after immunization. J Immunol. 1979; 123: 303– 310. 6 Lindahl P, Leary P, Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Ac-ad Sri USA. 1972; 69: 721– 725. 7 Basham TV, Smith WK, Merrigan TC. Interferon enhances anti-body-dependent cellular cytotoxicity when suboptimal concentrations of antibody are used. Cell Immunol. 1984; 88: 393– 400. 8 Smith FB, Blalock JF. The hormonal nature of the interferon system. Texas Reports on Biology and Medicine. 1982; 41: 350– 358. 9 Sarma PS, Shiu G, Baron S, et al. Inhibitory effect of interferon in murine sarcoma and leukemia virus in vitro. Nature, 1969; 223: 845– 846. 10 Clemens M. Interferons and oncogenes. Nature. 1985; 313: 531– 552. 11 Johnson MM, Baron S. The nature of the suppressive effect of interferon and interferon inducers on she in vitro immune response. Cell Immunol. 1976; 25: 106– 115. 12 Basham TY, Merrigan TC. Recombinant interferon gamma in-creases HLA-DR synthesis and expression. J Immunol. 1983; 130: 1492– 1494. 13 Guyre PM, Morganelli PM, Miller R. Recombinant immune in-terferon increase immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest. 1983; 72: 393– 397. 14 Blalock IE, Georgiades JA, Langford MR, et al. Purified human immune interferon has more potent anticellutar activity than fibroblast or leukocyte interferon. Cell Immunol. 1980; 49: 390– 394. 15 Fleischmann WR Jr. Potentiation of direct anticellular activity of mouse interferon: mutual synergism and interferon concentration dependence. Cancer Res. 1982: 42: 869– 875. 16 Tyring S, Klimpel G, Brysk M, et al. Eradication of cultured human melanoma cells by immune interferon and leukocytes. JNCI. 1984; 73: 1067– 1073. 17 Fleischmann WR jr, Schwarz LA, Fleischmann CM. Requirement for IFN gamma in potentiation of interferon's antiviral and anticellular activities: Identity of mouse and human systems. J Interferon Res. 1984: 4: 265– 274. 18 Fleischmann WR jr, Fleischmann CM. Potentiating effect of murine-gamma-containing lymphokine preparation of the antiviral and antiproliferative effects of murine interferon alpha/beta: identification of the potentiation factor as murine interferon gamma itself. Antiviral Res. 1984; 4: 22l– 228. 19 Iaude H, LaBonnardiere C. Cytocidal effect of interferons on porcine renal cells. Interferon Res. 1984: 4: 221– 228. 20 Zarling JM, Sosman J, Eskra L, et al. Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. Immunol. 1978; 121: 2002– 2004. 21 Pace J, Russel SW, LeBlanc PA. Comparative effects of various classes of mouse interferons on macrophage activation for tumor cell killing. I Immunol. 1985; 134: 977– 981. 22 Trinchieri G, Granato D, Perussia B. Interferon-induced resistance of fibroblasts to cytolysis mediated by natural killer cells: specificity and mechanism. I Immunol. 1981; 126: 335– 340. 23 Sarzotti M, Baron S, Tyring SK, et al. Interferon-mediated protection of B-16 melanoma cells from cytotoxicity by activated macrophages. Cell Immunol. 1983; 100: 280– 287. 24 Wallach D. Interferon-induced resistance to the killing by NK cells: A preferential effect of IFN gamma. Cell Immunol. 1983; 75: 390– 395. 25 Weigent DA, Langford MP, Fleischmann WR Jr, et al. Potentiation of lymphocyte natural killing by mixtures of alpha or beta interferon with recombinant gamma interferon. Infect Immun. 1983; 40: 35– 38. 26 Weigent DA, Langford MP, Fleischmann WR Jr, et al. Enhancement of natural killing activity by different types of interferon. In: A Kahn, NO Hill, eds. Human. Lymphokines. New York : Academic Press, 1982: 539– 550. 27 Brysk MM, Tyring SK, Miller J, et al. Anticellular actions of interferon in vitro parallel those in vivo against the murine epidermal JB-8 cell line. J Invest Dermatol, 1984; 82: 402A. 28 Brenning G, Ahre A, Nilsson K. Correlation between in vitro and in vivo sensitivity to human leukocyte interferon in patients with multiple myeloma. Scand I Haematol. 1985; 35: 543– 549. 29 Chany C, Rousset S, Chany-Fournier F. Role of membrane receptors in the biological effects of interferon. Texas Reports on Biology and Medicine. 1982; 41: 307– 312. 30 Ball LA, West DK. 2′,5′-oligoadenylate synthetase in inter-feron-treated chick cells. Tex Rep Biol Med. 1982; 41: 487– 492. 31 Rosenblum MG, Maxwell BL, Talpaz M, et al. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase. Cancer Res, 1986; 4b: 4848– 4852. 32 Chany C, Vignal M. Effect of prolonged interferon treatment on mouse embryonic fibroblasts transformed by murine sarcoma virus. J Gen Virol. 1970; 7: 203– 210. 33 Brouty-Boye' D, Gresser I. Studies on the reversibility of the transformed and neoplastic phenotype. I. Progressive reversion of the phenotype of x-ray transformed CBH/10TI/2 cells under prolonged treatment with interferon. Int J Cancer. 1981; 28: 165– 173. 34 Johnson HM, Smith BG, Baron S. Inhibition of the primary in vitro antibody response by interferon preparations. J Immunol. 1975; 114: 403– 409. 35 Sonnefeld G, Mandel Ad, Merrigan TC. Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Cell Immunol. 1978; 40: 285– 293. 36 Stringfellow DA. Interferon induction: hyporesponsiveness and prostaglandins. Tex Rep Biol Med. 1982; 41: 116– 121. 37 Quesada JR, Reuben J, Manning JT, et al. Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med. 1984: 310: 15– 18. 38 Talpaz M, Kantarjian HM, McCredie K, et al. Hemalologic remission and cytogenetic improvement induced by recombinant human inlerferon alpha in chronic myelogenous leukemia. N Engl J Med. 1986: 314: 1065– 1069. 39 Dunn BA, Ihde DC, Foon KA. The role of recombinant inter feron alfa-2a in the therapy of cutaneous T cell lymphomas. Cancer. 1986; 57: 1689– 1695. 40 Ohno R, Kimura K. Treatment of multiple myeloma with recombinant interferon alfa-2A. Cancer. 1986; 57: 1685– 1688. 41 Foon KA, Sherwin SA, Abrams PC, et al. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A in-terferon. N Engl I Med. 1984: 311: 1148– 1152. 42 Taguchi T. Clinical studies of recombinant interferon alfa-2a (Roferon®-A) in cancer patients. Cancer. 1986; 57: 1705– 1708. 43 Quesada JR, Talpaz M, Rio SA, et al. Clinical toxicity of inter-ferons in cancer patients: a review. I Clin Oncol, 1986: 4: 234– 243. 44 Neidhart JA. Interferon therapy for the treatment of renal cancers. Cancer. 1986; 57: 1696– 1699. 45 Legha SS. Interferons in the treatment of malignant melanoma: a review of recent trials. Cancer. 1986; 57: 1675– 1677. 46 Krown SE, Real FX, Vadhan-Raj S, et al. Kaposi's sarcoma and the acquired immune deficiency syndrome: treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer. 1986; 57: 1662– 1665. 47 Gissmann L, Boshart M, Durst M, et al. Presence of human papillomavirus in genital tumors. Invest Dermatol. 1984; 83: 26s– 28s. 48 Schonfeld A, Schattner A, Crespi M, et al, Intramuscular human interferon B injections in treatment of condyloma acuminata. Lancet. 1984; 1; 1038– 1042. 49 Gall SA, Hughes CE, Trofatter K. Interferon for the therapy of condyloma acuminatum Am J Obstet Gynecol. 1985; 153: 157– 163. 50 Gall SA, Hughes CE, Mount SP, et al. Efficacy of human lym-phoblastoid interferon in the therapy of resistant condyloma acuminata. Obstet Gynecol. 1986; 67: 643– 651. 51 Reichman RC, Bonnez W, Greisberger C, et al. Treatment of condyloma acuminatum with intralesirmally administered interferons: a multicentered, placebo-controlled trial. Clin Res, 1986; 34: 531A. 52 Vance IC, Bart B, Hansen RC, et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca planteris. Arch Dermatol, 1986: 122: 272– 277. 53 Kirby P, Wells D, Kiviat N, et al. A phase I trial of intramuscular recombinant human gamma interferon for refractory genital warts. J Invest Dermatol. 1988; 86: 485A. 54 Strander HA. Interferon in the treatment of human papilloma virus. Med Clin North Am. 1986 May; Suppl: 19– 23. 55 Goepfert H, Sessions RB, Gutterman JU, et al. Leukocyte interferon in patients with juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol. 1982: 91: 431– 436: 56 McCabe B, Clark KF. Interferon and laryngeal papillomatosis. Ann Otol Rhinol Laryngol. 1983; 92: 2– 7. 57 Lodemann E, Komhuber B, Gerein V, et al. (2′-5′) Oligo (A) synthetase as a monitor of interferon action in juvenile laryngeal papillomatosis. J Interferon Res. 1984; 4: 283– 290. 58 Borden EC. Progress toward therapeutic application of inter- feron, 1979 1983. Cancer. 1984; 54: 2770– 2776. 59 Horoszewicz JS, Leong SS, Ito M, et al. Human fibroblast interferon in human neoplasia: clinical and laboratory study. Cancer Treat Rep. 1978: 62: 1899– 1906. 60 Treuner J, Niethammer D, Dannecker G, et al. Successful treatment of nasopharyngeal carcinoma with interferon. Lancet. 1980; 1: 817– 818. 61 Hawkins MJ, Krown SE, Borden EC, et al. American Cancer Society phase I trials of naturally produced beta-interferon. Cancer Res. 1984; 44: 5934– 5938. 62 Harris J, Das Gupta T, Vogelzang N, et al. Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study. Cancer Treat Rep. 1986: 70: 293– 294. 63 Rinehart J, Malspeis L, Young D, et al. Phase I/II trial of human recombinant beta-intorferon serine in patients with renal cell carcinoma. Cancer Res. 1986: 46: 5364– 5367. 64 Foon KA, Sherwin SA, Abrams PC, et al. A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immuno Ther. 1985; 20: 193– 197. 65 Van Der Burg M, Edelson M, Gerlis L, et al. Recombinant interferon gamma (Immureson): results of a phase I trial in patients with cancer. J Biol Response Mod. 1985; 4: 264– 272. 66 Vadhan-Raj S, Nathan CF, Sherwin SA, et al. Phase I trial of recombinant interferon gamma by 1 hour I.V. infusion. Cancer Treat Rep. 1986; 5: 609– 614. 67 Branca AA, Baglioni C. Evidence that type I and type II interferons have different receptors. Nature. 1981: 294: 768– 770. 68 Fleischmann WR Jr, Newton RC, Fleischmann CM. et al. Discrimination between nonmalignant and malignant cells by combinations of IFN gamma plus IFN alpha/beta. J Biol Response Mod. 1984; 3: 397– 405. 69 Kirkwood JM, Ernstoff MS. Interferons in the treatment of cancer. J Clin Oncol. 1984; 2: 336– 352. 70 Herberman RB. Design of clinical trials with biological response modifiers. Cancer Treat Rep. 1985; 69: 1161– 1164. 71 Creasey AA, Bartholomew JC, Merrigan TC. Role of G0-G1, arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA. 1980, 77: 1471– 1475. 72 Hirabayski W, Nishiyama M, Yamaguchi M, et al. Assessment of the combined effects of mitomycin C with alpha interferon or gamma interferon by the clonogenic assay technique. Can To Kagaku Ryoho. 1985; 12: 1056– 1062. 73 Dune GMD, Clouse L, Braich T, et al. Interferon alfa-2b-cyclo-phosphamide combination studies: In vitro and phase I-II clinical results. Semin Oncol. 1986: 13: 84– 88. 74 Sarosy GA, Brown TD, Von Hoff DD, et al. Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors. Cancer Res. 1986; 46: 5368– 5371. 75 Cooper MR, Fefer A, Thompson J, et al. Alpha 2 interferon/ melphalan/prednisone in previously untreated patients with multiple myeloma: A phase I-II trial. Cancer Treat Rep. 1986; 70: 473– 476. 76 Fossa SD, DeGaris JT, Heier MS, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer. 1986; 57: 1700– 1704. 77 Bennett CL, Vogelzang NJ, Ratain MJ, et al. Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. Cancer Treat Rep. 1986, 70: 1081– 1084. 78 Namba M, Yamamoto S, Tanaka Fl, et al. In vitro and in vivo studies on protentiation of cytotoxic drugs or cobalt 60 gamma ray by interferon on human neoplastic cells. Cancer. 1984; 54: 2262– 2267. 79 Chang AYC, Keng PC. Inhibition of cell growth in synchronous human hypernephroma cells by recombinant interferon alpha-D and irradiation. J Interferon Res. 1983: 3: 379– 385. 80 Chang AYC, Keng PC. Effects of gamma interferon and radiation on synchronized human hypernephroma cells. Proceedings of the American Association for Cancer Research. 1985; 26: 28A. 81 Wasserman J, Baral E, Biberfeld G, et al. Effect of in vitro irradiation on lymphocyte subpopulations and cytotoxicity. In: JB Dubois, B Serrou, C Rosenfeld, eds. Immunopharmacologic Effects of Radiation Therapy. New York : Raven Press, 1981: 123– 135. 82 Seltzer V, Doyle A, Kadish AS. Natural cytotoxicity in malignant and premalignant cervical neoplasia and enhancement of cytotoxicity with interferon, Gynecol Oncol. 1983; 15: 340– 349. 83 Torrisi J, Berg C, Bonnem E, et al. The combined use of interferon and radiotherapy in cancer management. Semin Oncol. 1986; 13: 78– 83. 84 Heron I, Berg K. The actions of interferon are potentiated at elevated temperatures. Nature. 1978: 274: 508– 510: 85 Fleischmann WR Jr, Fleischmann CM, Gindhart TD. Effect of hyperthermia on the antiproliferative activities of murine alpha-, beta-, and gamma-interferon: differential enhancement of murine gamma interferon. Cancer Res. 1986; 46: 8– 13. 86 Fleischmann WR Jr, Fleischmann CM, Cindhart TD. Effect of hyperthermia on combination interferon treatment: enhancement of the antiproliferative activity against murine B 16 melanoma. Cancer Res, 1986; 46: 1722– 1726. 87 Itoh K, Shiiba K, Shimizu Y, et al. Generation of activated killer cells by recombinant interleukin 2 (r IL-2) in collaboration with interferon gamma (IFN gamma). J Immunol. 1985; 134: 3124– 3129. 88 Lee SH, Aggarwal BB, Rinderknecht E, et al. The synergistic antiproliferative effect of gamma interferon and human lym-photoxin. J Immunol. 1984; 133: 1083– 1086. 89 Soehnlen B, Liu R, Salmon SE. Recombinant tumor necrosis factors exhibit antitumor activity against clonagenic tumor cells and synergism with gamma interferon. Proceedings of the American Association for Cancer Research. 1985; 26: 303A. Citing Literature Volume26, Issue9November 1987Pages 549-556 ReferencesRelatedInformation